In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 9, 1996, Pages 2232-2235

  Wexler, Hannah M ^a,b   Molitoris, Eric ^b   Molitoris, Denise ^a   Finegold, Sydney M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; IMIPENEM; METRONIDAZOLE; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTEROIDES FRAGILIS; CAMPYLOBACTER; CLOSTRIDIUM; CONTROLLED STUDY; FUSOBACTERIUM; PEPTOSTREPTOCOCCUS; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL;

EID: 0029795727     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.9.2232     Document Type: Article

References (23)

1. Barry, A. L., P. C. Fuchs, D. M. Citron, S. D. Allen, and H. M. Wexler. 1993. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J. Antimicrob. Chemother. 31:893-900.
2. Bauernfeind, A. 1993. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J. Antimicrob. Chemother. 31:505-522.
3. Clarke, A. M., and S. J. Zemcov. 1989. Comparative in vitro activity of tomefloxacin, a new difluoroquinolone. Eur. J. Clin. Microbiol. Infect. Dis. 8:164-168.
4. Fernandes, P. B., N. Shipkowitz, R. K. Bower, K. P. Jarvis, J. Weisz, and D. T. Chu. 1986. In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria. J. Antimicrob. Chemother. 18:693-701.
5. Fox, A. R., and I. Phillips. 1987. The antibiotic sensitivity of the Bacteroides fragilis group in the United Kingdom. J. Antimicrob. Chemother. 20:477-488.
6. Goldstein, E. J., and D. M. Citron. 1992. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob. Agents Chemother. 36:1158-1162.
7. Goldstein, E. J. C., and D. M. Citron. 1985. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals. Antimicrob. Agents Chemother. 27:657-659.
8. Holdeman, L. V., E. P. Cato, and W. E. C. Moore. 1977. Anaerobe laboratory manual. Virginia Polytechnic Institute and State University, Blacksburg.
9. Jones, B. M., I. Geary, M. E. Lee, and B. I. Duerden. 1986. Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections. J. Antimicrob. Chemother. 17: 739-746.
10. King, A., and I. Phillips. 1986. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J. Antimicrob. Chemother. 18(Suppl. D):1-20.
11. Marshall, S. A., and R. N. Jones. 1993. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob. Agents Chemother. 37:2747-2753.
12. National Committee for Clinical Laboratory Standards. 1993. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd ed. Approved standard M11-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. Sato, K., K. Hoshino, M. Tanaka, I. Hayakawa, and Y. Osada. 1992. Anti-microbial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemother. 36:1491-1498.
14. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
15. Summanen, P., E. J. Baron, D. Citron, C. Strong, H. M. Wexler, and S. M. Finegold. 1993. Wadsworth Anaerobic Bacteriology Manual. Star Publishing Company, Belmont, Calif.
16. Sutter, V. L., Y. Y. Kwok, and J. Bulkacz. 1985. Comparative activity of ciprofloxacin against anaerobic bacteria. Antimicrob. Agents Chemother. 27:427-428.
17. Thomson, K. S., C. C. Sanders, and W. E. Sanders, Jr. 1993. DU-6859a, a new quinolone highly active against certain ciprofloxacin-resistant bacteria, abstr. 989, p. 300. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Venezia, R. A., D. M. Yocum, E. M. Robbiano, and R. M. Echols. 1990. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria. Antimicrob. Agents Chemother. 34:1858-1861.
19. Watt, B., and F. V. Brown. 1986. Is ciprofloxacin active against clinically important anaerobes? J. Antimicrob. Chemother. 17:605-613.
20. Wexler, H. M., E. Molitoris, and S. M. Finegold. 1992. In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrob. Agents Chemother. 36:239-243.
21. Wexler, H. M., E. Molitoris, D. Reeves, and S. M. Finegold. 1994. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria. J. Antimicrob. Chemother. 34:579-584.
22. Wexler, H. M., E. Molitoris, D. Reeves, and S. M. Finegold. 1994. In vitro activity of DU-6859a against anaerobic bacteria. Antimicrob. Agents Chemother. 38:2504-2509.
23. Wexler, H. M., D. Reeves, P. Summanen, E. Molitoris, M. McTeague, J. Duncan, K. H. Wilson, and S. M. Finegold. 1996. Sutterella wadsworthensis gen. nov., sp. nov., bile-resistant microaerophilic Campylobacter gracilis-like clinical isolates. Int. J. Syst. Bacteriol. 46:252-258.